Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins.
about
Pathogenesis of human immunodeficiency virus infectionNeutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes.Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.Effect of nonprotective vaccination on antibody response to subsequent human immunodeficiency virus infection.Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workersA conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1The tale of the long tail: the cytoplasmic domain of HIV-1 gp41.Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody.Evidence against extracellular exposure of a highly immunogenic region in the C-terminal domain of the simian immunodeficiency virus gp41 transmembrane proteinAntibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation.Antigenic conservation and immunogenicity of the HIV coreceptor binding siteThe membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine designAntibodies of symptomatic human immunodeficiency virus type 1-infected individuals are directed to the V3 domain of noninfectious and not of infectious virions present in autologous serum.Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization.B epitopes and selection pressures in feline immunodeficiency virus envelope glycoproteins.Multivariate analysis of human immunodeficiency virus type 1 neutralization dataSoluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses.Characterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1Delayed infection after immunization with a peptide from the transmembrane glycoprotein of the feline immunodeficiency virus.Location, exposure, and conservation of neutralizing and nonneutralizing epitopes on human immunodeficiency virus type 2 SU glycoproteinA neutralizing monoclonal antibody previously mapped exclusively on human immunodeficiency virus type 1 gp41 recognizes an epitope in p17 sharing the core sequence IEEE.Identification of the V1 region as a linear neutralizing epitope of the simian immunodeficiency virus SIVmac envelope glycoprotein.Evolution of the human immunodeficiency virus type 2 envelope gene in preimmunized and persistently infected rhesus macaques.Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.A Plant-Derived Multi-HIV Antigen Induces Broad Immune Responses in Orally Immunized Mice.Towards covalent vaccination: improved polyclonal HIV neutralizing antibody response induced by an electrophilic gp120 V3 peptide analog.HIV-1 binding and neutralizing antibodies of injecting drug users.Expression and immunological characterization of cardamom mosaic virus coat protein displaying HIV gp41 epitopes.Multi-subtype gp160 DNA immunization induces broadly neutralizing anti-HIV antibodies.
P2860
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
P2860
Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Identification of human neutra ...... type 1 envelope glycoproteins.
@en
type
label
Identification of human neutra ...... type 1 envelope glycoproteins.
@en
prefLabel
Identification of human neutra ...... type 1 envelope glycoproteins.
@en
P2093
P2860
P356
P1476
Identification of human neutra ...... type 1 envelope glycoproteins.
@en
P2093
Broliden PA
von Gegerfelt A
P2860
P304
P356
10.1073/PNAS.89.2.461
P407
P577
1992-01-01T00:00:00Z